+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Respiratory Tract Infection Therapeutic Market Research Report by Drugs, Disease Indication, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 252 Pages
  • October 2022
  • Region: Global
  • 360iResearch™
  • ID: 4985879
UP TO OFF until Dec 31st 2022
The Global Respiratory Tract Infection Therapeutic Market size was estimated at USD 39.17 billion in 2021, USD 42.11 billion in 2022, and is projected to grow at a CAGR of 7.69% to reach USD 61.11 billion by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Respiratory Tract Infection Therapeutic to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drugs, the market was studied across Antibiotics, Cough Suppressants, Nasal Decongestants, and Non-steroidal Anti-inflammatory Drugs.
  • Based on Disease Indication, the market was studied across Lower Respiratory Tract Infection and Upper Respiratory Tract Infection.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Respiratory Tract Infection Therapeutic market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Respiratory Tract Infection Therapeutic Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Respiratory Tract Infection Therapeutic Market, including Abbott, AbbVie Inc., Allergan, Apotex Corporation, Ascend Laboratories Ltd, AstraZeneca, Auro Pharma Inc, Aurobindo Pharma, AuroMedics Pharma LLC, Bristol-Myers Squibb Company, Cardinal Health, Claris Lifesciences, Inc., F. Hoffmann-La Roche Ltd, Fresenius Kabi USA, LLC, GlaxoSmithKline plc, Hikma Pharmaceuticals USA Inc., Hospira, Inc., Laboratorios Quimica Son's, S.A. de C.V, Merck & Co., Inc., Novartis AG, Pfizer Inc., Physicians Total Care, Inc., Piramal Critical Care Inc, Pragma Pharmaceuticals, LLC, Sandoz Inc, Teva Pharmaceutical Industries Ltd., and WG Critical Care, LLC.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Respiratory Tract Infection Therapeutic Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Tract Infection Therapeutic Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Tract Infection Therapeutic Market?
4. What is the competitive strategic window for opportunities in the Global Respiratory Tract Infection Therapeutic Market?
5. What are the technology trends and regulatory frameworks in the Global Respiratory Tract Infection Therapeutic Market?
6. What is the market share of the leading vendors in the Global Respiratory Tract Infection Therapeutic Market?
7. What modes and strategic moves are considered suitable for entering the Global Respiratory Tract Infection Therapeutic Market?
Frequently Asked Questions about the Global Respiratory Tract Infection Therapeutic Market

What is the estimated value of the Global Respiratory Tract Infection Therapeutic Market?

The Global Respiratory Tract Infection Therapeutic Market was estimated to be valued at $39.17 Billion in 2021.

What is the growth rate of the Global Respiratory Tract Infection Therapeutic Market?

The growth rate of the Global Respiratory Tract Infection Therapeutic Market is 7.6%, with an estimated value of $61.11 Billion by 2027.

What is the forecasted size of the Global Respiratory Tract Infection Therapeutic Market?

The Global Respiratory Tract Infection Therapeutic Market is estimated to be worth $61.11 Billion by 2027.

Who are the key companies in the Global Respiratory Tract Infection Therapeutic Market?

Key companies in the Global Respiratory Tract Infection Therapeutic Market include Abbott, AbbVie Inc., Allergan, Apotex Corporation, Ascend Laboratories Ltd, AstraZeneca, Auro Pharma Inc, Aurobindo Pharma and Bristol.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased reports cases of asthma and respiratory trac infection
5.1.1.2. Changing Lifestyle and geriatric population
5.1.1.3. Increase development of generic drugs and biosimilars in the space
5.1.2. Restraints
5.1.2.1. Seasonal indications and inspections
5.1.3. Opportunities
5.1.3.1. Investment in drug development and commercialization
5.1.3.2. Technology development in drug delivery systems
5.1.4. Challenges
5.1.4.1. Emergence of antimicrobial resistance
5.2. Cumulative Impact of COVID-19
6. Respiratory Tract Infection Therapeutic Market, by Drugs
6.1. Introduction
6.2. Antibiotics
6.3. Cough Suppressants
6.4. Nasal Decongestants
6.5. Non-steroidal Anti-inflammatory Drugs
7. Respiratory Tract Infection Therapeutic Market, by Disease Indication
7.1. Introduction
7.2. Lower Respiratory Tract Infection
7.3. Upper Respiratory Tract Infection
8. Respiratory Tract Infection Therapeutic Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Respiratory Tract Infection Therapeutic Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Respiratory Tract Infection Therapeutic Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AbbVie Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Allergan
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Apotex Corporation
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Ascend Laboratories Ltd
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. AstraZeneca
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Auro Pharma Inc
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Aurobindo Pharma
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. AuroMedics Pharma LLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Bristol-Myers Squibb Company
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Cardinal Health
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Claris Lifesciences, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. F. Hoffmann-La Roche Ltd
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Fresenius Kabi USA, LLC
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. GlaxoSmithKline plc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Hikma Pharmaceuticals USA Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Hospira, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Laboratorios Quimica Son's, S.A. de C.V
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Merck & Co., Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Novartis AG
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Pfizer Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Physicians Total Care, Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Piramal Critical Care Inc
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Pragma Pharmaceuticals, LLC
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Sandoz Inc
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Teva Pharmaceutical Industries Ltd.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. WG Critical Care, LLC
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET DYNAMICS
FIGURE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2021 VS 2027 (%)
FIGURE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUGS, 2027
FIGURE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2027 (USD BILLION)
FIGURE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, 2018-2027 (USD BILLION)
FIGURE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, 2018-2027 (USD BILLION)
FIGURE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2027 (USD BILLION)
FIGURE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2021 VS 2027 (%)
FIGURE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY DISEASE INDICATION, 2027
FIGURE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2027 (USD BILLION)
FIGURE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2027 (USD BILLION)
FIGURE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2027
FIGURE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2027 (USD BILLION)
FIGURE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD BILLION)
FIGURE 28. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2027 (USD BILLION)
FIGURE 29. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 30. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 31. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 32. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 33. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 34. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 35. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 36. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 37. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 38. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 39. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 40. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 41. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 42. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 43. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 44. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 45. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 46. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 47. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 48. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 49. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 50. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 51. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 52. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 53. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 54. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 55. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 56. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 61. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 62. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 63. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 64. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 65. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 66. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 67. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 68. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 69. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 70. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 71. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 72. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 73. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 74. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 75. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 76. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 77. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 78. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 79. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 80. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 81. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 82. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 83. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 84. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2027 (USD BILLION)
TABLE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2027 (USD BILLION)
TABLE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2027 (USD BILLION)
TABLE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2027 (USD BILLION)
TABLE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, 2018-2027 (USD BILLION)
TABLE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, 2018-2027 (USD BILLION)
TABLE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2027 (USD BILLION)
TABLE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2027 (USD BILLION)
TABLE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2027 (USD BILLION)
TABLE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2027 (USD BILLION)
TABLE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2027 (USD BILLION)
TABLE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2027 (USD BILLION)
TABLE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2027 (USD BILLION)
TABLE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2027 (USD BILLION)
TABLE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2027 (USD BILLION)
TABLE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2027 (USD BILLION)
TABLE 28. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 29. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 30. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD BILLION)
TABLE 31. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 32. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 33. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2027 (USD BILLION)
TABLE 34. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 35. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 36. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 37. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 38. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 39. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 40. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 41. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 42. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 43. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 44. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 45. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 46. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 47. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 48. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 49. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 50. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 51. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 52. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 53. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 54. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 55. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 56. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 57. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 58. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2027 (USD BILLION)
TABLE 59. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 60. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 61. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 62. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 63. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 64. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 65. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 66. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 67. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 68. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 69. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 70. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 71. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 72. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 73. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 74. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 75. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 76. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 77. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 78. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 79. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 80. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 81. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 82. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 83. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 84. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 85. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 86. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 87. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 88. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 89. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 90. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 91. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 92. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 93. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 94. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 95. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 96. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 97. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 98. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 99. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 100. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 101. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 102. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 103. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 104. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 105. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 106. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 107. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 108. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 109. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 110. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 111. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 112. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 113. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 114. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 120. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 121. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 122. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 123. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 124. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 125. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 126. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 127. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 128. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 129. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 130. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 131. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 132. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 133. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 134. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 135. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 136. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 137. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 138. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 139. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 140. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 141. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 142. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 143. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 144. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 145. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 146. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 147. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 148. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 149. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 150. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 151. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 152. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 153. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 154. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 155. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 156. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 157. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 158. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 159. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 160. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 161. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 162. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 163. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 164. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 165. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 166. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 167. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 168. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 169. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 170. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 171. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 172. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 173. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 174. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 175. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 176. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 177. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 178. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 179. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 180. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 181. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 182. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 183. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 184. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 185. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 186. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 187. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 188. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 189. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 190. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 191. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 192. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 193. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 194. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 195. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 196. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 197. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 198. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 199. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 200. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 201. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2027 (USD BILLION)
TABLE 202. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2027 (USD BILLION)
TABLE 203. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
TABLE 204. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 205. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 206. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 207. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RANKING, BY KEY PLAYER, 2021
TABLE 208. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2021
TABLE 209. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET MERGER & ACQUISITION
TABLE 210. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 211. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 212. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET INVESTMENT & FUNDING
TABLE 213. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 214. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott
  • AbbVie Inc.
  • Allergan
  • Apotex Corporation
  • Ascend Laboratories Ltd
  • AstraZeneca
  • Auro Pharma Inc
  • Aurobindo Pharma
  • AuroMedics Pharma LLC
  • Bristol-Myers Squibb Company
  • Cardinal Health
  • Claris Lifesciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi USA, LLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals USA Inc.
  • Hospira, Inc.
  • Laboratorios Quimica Son's, S.A. de C.V
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Physicians Total Care, Inc.
  • Piramal Critical Care Inc
  • Pragma Pharmaceuticals, LLC
  • Sandoz Inc
  • Teva Pharmaceutical Industries Ltd.
  • WG Critical Care, LLC

Methodology

Loading
LOADING...